TREATMENT OF DISEASES CAUSED BY ABNORMAL LYMPHOCYTE FUNCTION WITH AN HDAC6 INHIBITOR
Number of patents in Portfolio can not be more than 2000
United States of America Patent
Stats
-
N/A
Issued Date -
Aug 11, 2016
app pub date -
Sep 19, 2014
filing date -
Sep 20, 2013
priority date (Note) -
Published
status (Latency Note)
Importance
|
US Family Size
|
Non-US Coverage
|
Abstract
An HDAC6 inhibitor (a compound of Formula I) is shown to reduce the pathogenesis associated with the B cell mediated autoimmune disease, systemic lupus erythematosus (SLE) Administration of a compound of Formula I attenuated many of the symptoms characteristic of SLE including splenomegaly, abnormal B cell differentiation, an increase in the number double-negative thymic T cells, an increase in the level of auto-antibodies such as anti-dsDNA, immune complex-mediated glomerulonephritis and an increase in inflammatory cytokine production. Treatment with a compound of Formula I also increased the number of the subject's splenic Treg cells while removing circulating auto-antibodies Inhibition of HDAC6 altered bone marrow B cell differentiation by increasing the percentage of cells in the early-stage developmental fractions of both pro- and pre-B cells. These results demonstrate HDAC6 inhibition with a compound of Formula I can treat SLE disease by altering aberrant T and B cell differentiation.
First Claim
Other Claims data not available
Family
| Country | kind | publication No. | Filing Date |
|---|---|---|---|
| EP | A1 | EP3046559 | Sep 19, 2014 |
| JP | A | JP2016531163 | Sep 19, 2014 |
| WO | A1 | WO2015042418 | Sep 19, 2014 |
International Classification(s)
- 2014 Application Filing Year
- A61K Class
- 14144 Applications Filed
- 11600 Patents Issued To-Date
- 82.02 % Issued To-Date
Cited Art Landscape
Patent Citation Ranking
- 7 Citation Count
- A61K Class
- 38.16 % this patent is cited more than
- 9 Age